AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16772027
Drug: PD off
RxNorm normalized name: Off! Explore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD off medication
Trial: 11808969
Drug: Placebo (once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (once weekly)
Trial: 11808969
Drug: Aspirin (650
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (650 mg q.i.d. for last week)
Trial: 28610605
Drug: Treatment completion
RxNorm normalized name: piperonyl butoxide
DrugBank: Piperonyl butoxide (DB09350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment completion
Trial: 7569760
Drug: Oral cromolyn
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cromolyn sodium (1500 mg/day) for 1 month
Trial: 27206923
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment including denture placement immediately after extractions
Trial: 23107353
Drug: Insulin infusion
RxNorm normalized name: iLet Insulin Infusion 10-Pack Kit Inset
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin infusion site warming device (InsuPatch)
Trial: 12837861
Drug: Exercise group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise group (n = 12); daily extension and flexion range of motion against passive resistance (5 minutes per day, 5 days per week, for 4 weeks)
Trial: 8794955
Drug: Inhaled methanol
RxNorm normalized name: methanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled methanol at 200 ppm for 4 hours
Trial: 2004725
Drug: 0.8 mg
RxNorm normalized name: biotin 0.8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 mg intravitreal dexamethasone phosphate
Trial: 6346848
Drug: Hydrochlorothiazide, 50
RxNorm normalized name: HydroCHLOROthiazide, 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide, 50 mg
Trial: 6346848
Drug: Indapamide, 2.5
RxNorm normalized name: Indapamide, 2.5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indapamide, 2.5 mg
Trial: 20737518
Drug: Multi-vitamin/mineral supplement
RxNorm normalized name: NESTABS DHA Prenatal Multi-vitamin/Mineral Supplement with DHA/EPA KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-vitamin/mineral supplement (Supradyn)
Trial: 12947070
Drug: Clodronate 1,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clodronate 1,500 mg IV every 3 weeks + mitoxantrone 12 mg/m2 IV every 3 weeks + prednisone 5 mg orally bid
Trial: 12947070
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + mitoxantrone 12 mg/m2 IV every 3 weeks + prednisone 5 mg orally bid
Trial: 10493337
Drug: Conventional inactivated
RxNorm normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional inactivated influenza A vaccine
Trial: 8614525
Drug: 311C90 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 311C90 1 mg
Trial: 8614525
Drug: 311C90 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 311C90 5 mg
Trial: 8614525
Drug: 311C90 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 311C90 25 mg
Trial: 1533289
Drug: Intravenous m-chlorophenylpiperazine
RxNorm normalized name: m-phenylenediamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous m-chlorophenylpiperazine (MCPP) 0.06 mg/kg
Trial: 1533289
Drug: Intravenous m-chlorophenylpiperazine
RxNorm normalized name: m-phenylenediamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous m-chlorophenylpiperazine (MCPP) 0.08 mg/kg
Trial: 3919556
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of bepridil hydrochloride
Trial: 3919556
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg of bepridil hydrochloride
Trial: 3919556
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg of bepridil hydrochloride
Trial: 22743160
Drug: Motivational Enhancement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational Enhancement Therapy/Cognitive Behavioral Therapy (MET/CBT)
Trial: 20693799
Drug: Intravenous sotalol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sotalol (75 mg over 2.5 h)
Trial: 20693799
Drug: Oral sotalol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sotalol (80 mg)
Trial: 16151353
Drug: Prednisone (0.35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (0.35 mg/kg daily for 18 weeks)
Trial: 16151353
Drug: Diphenidol (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diphenidol (25 mg/d) plus acetazolamide (250 mg/48 h)
Trial: 10695780
Drug: Dihydroartemisinin 480
RxNorm normalized name: Succinyl dihydroartemisinin
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dihydroartemisinin 480 mg over 5 days
Trial: 10695780
Drug: Dihydroartemisinin 640
RxNorm normalized name: Succinyl dihydroartemisinin
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dihydroartemisinin 640 mg over 7 days
Trial: 7827868
Drug: Monoclonal antibody
RxNorm normalized name: Monoclonal antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal antibody (MAb) and complement treatment
Trial: 3163879
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg Zn/d
Trial: 3163879
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg Zn/d
Trial: 23180503
Drug: Protocolized sedation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocolized sedation plus daily sedation interruption (n = 214)
Trial: 20683334
Drug: Sugammadex 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex 2.0 mg kg(‐1)
Trial: 16180595
Drug: Daily stretch
RxNorm normalized name: Mederma Stretch Mark Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily stretch positioning for wrist and finger flexors and shoulder adductors and internal rotators, two 30-min stretches per day for up to 12 weeks post stroke.
Trial: 12796526
Drug: Antipsychotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic therapy
Trial: 8609746
Drug: Ceftriaxone 2
RxNorm normalized name: ceftriaxone 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 2 g single preoperative dose
Trial: 25250613
Drug: Sitafloxacin 50
RxNorm normalized name: Finafloxacin
DrugBank: Finafloxacin (DB09047)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sitafloxacin 50 mg
Trial: 25250613
Drug: Sitafloxacin 100
RxNorm normalized name: Finafloxacin
DrugBank: Finafloxacin (DB09047)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sitafloxacin 100 mg
Trial: 25250613
Drug: Sitafloxacin 200
RxNorm normalized name: Finafloxacin
DrugBank: Finafloxacin (DB09047)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sitafloxacin 200 mg
Trial: 17548731
Drug: Intravenous cooling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cooling with 4 degrees C normal saline (500 to 2000 mL)
Trial: 15562142
Drug: Aerosolized tobramycin
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Aerosolized tobramycin (300 mg twice daily for 6 months)
Trial: 9539304
Drug: Ovine corticotropin-releasing
RxNorm normalized name: Ovine corticotropin-releasing factor
DrugBank: Corticorelin ovine triflutate (DB09067)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ovine corticotropin-releasing hormone (oCRH) 1 microg/kg body weight
Trial: 9539304
Drug: Low-dose ACTH
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ACTH 5 microg i.v.
Trial: 1776334
Drug: molsidomine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: molsidomine (4 mg)
Trial: 1776334
Drug: isosorbide‐5‐mononitrate (ISMN,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: isosorbide‐5‐mononitrate (ISMN, 20 mg)
Trial: 30942510
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg of saffron (two pills per day) for 3 months
Trial: 30942510
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules (two pills per day) for 3 months
Trial: 20226444
Drug: Metformin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin plus leuprolide acetate (LA) placebo
Trial: 16236177
Drug: Tigecycline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tigecycline (100 mg initial dose, then 50 mg every 12 hours for 5 to 14 days)
Trial: 16236177
Drug: Imipenem/cilastatin (500/500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipenem/cilastatin (500/500 mg every 6 hours or adjusted for renal dysfunction for 5 to 14 days)
Trial: 11940029
Drug: Botulinum neurotoxin
RxNorm normalized name: Botulinum neurotoxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum neurotoxin Type A (BoNTA) intramuscular injections to triceps surae (800 U Dysport) and functional electrical stimulation (FES) of the common peroneal nerve with physiotherapy
Trial: 2228399
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg dl-fenfluramine/meal
Trial: 2228399
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg dl-fenfluramine/no meal
Trial: 25707693
Drug: 3-antigen Staphylococcus
RxNorm normalized name: STAPHYLOCOCCUS EPIDERMIDIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-antigen Staphylococcus aureus vaccine (SA3Ag)
Trial: 17451692
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (nonobese PCOS patients without insulin resistance)
Trial: 15075548
Drug: AIDSVAX B/E
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AIDSVAX B/E HIV vaccine trial participation
Trial: 11158948
Drug: Acute ascorbic
RxNorm normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acute ascorbic acid treatment (2 g po)
Trial: 11158948
Drug: Chronic ascorbic
RxNorm normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic ascorbic acid treatment (500 mg/day for 1 month)
Trial: 29512838
Drug: Stabilisation splint
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stabilisation splint treatment
Trial: 27590017
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg PPS
Trial: 27590017
Drug: 2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg PPS
Trial: 23804582
Drug: Lifestyle change
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lifestyle change with metformin
Trial: 23804582
Drug: Lifestyle change
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lifestyle change without metformin
Trial: 20827195
Drug: Bortezomib-based chemotherapy
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib-based chemotherapy
Trial: 20827195
Drug: Novel chemotherapy
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Novel chemotherapy agents
Trial: 18983759
Drug: N-acetyl cysteine
RxNorm normalized name: N-Acetyl Cysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetyl cysteine (NAC) 0.6 g + folic acid 500 microg/day
Trial: 16025785
Drug: Intensive acupuncture
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive acupuncture treatment (10 sessions over 3-4 weeks)
Trial: 16025785
Drug: Sham acupuncture
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham acupuncture treatment (control group)
Trial: 8964646
Drug: Diet and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet and lipid-lowering drugs
Trial: 6113797
Drug: Meprobamate (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meprobamate (250 mg)
Trial: 23769121
Drug: Control plus
RxNorm normalized name: SODIUM FLUORIDE 2.4 mg in 1 g DENTAL GEL, DENTIFRICE [AIM TARTAR CONTROL Plus Mouthwash and Whitening]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control plus HBO therapy
Trial: 23769121
Drug: I/R plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I/R plus HBO therapy
Trial: 19403877
Drug: 0.1 mg
RxNorm normalized name: biotin 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg rhTSH/24-h interval
Trial: 15476903
Drug: ProSorb diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ProSorb diclofenac K 25 mg
Trial: 15476903
Drug: ProSorb diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ProSorb diclofenac K 50 mg
Trial: 15476903
Drug: ProSorb diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ProSorb diclofenac K 100 mg
Trial: 11681767
Drug: Transdermal nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal nicotine (7 mg/24 hours)
Trial: 9603132
Drug: Topical soft
RxNorm normalized name: Della Soft Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical soft tissue lubricant
Trial: 29458316
Drug: Energy-dense formulation
RxNorm normalized name: Senergy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Energy-dense formulation (1.5 kcal/mL)
Trial: 29458316
Drug: Routine enteral
RxNorm normalized name: lipase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine enteral feed formulation (1 kcal/mL)
Trial: 9595924
Drug: Tamoxifen 10
RxNorm normalized name: tamoxifen 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen 10 mg by mouth from day 5 to day 24 of the menstrual cycle
Trial: 9595924
Drug: Placebo 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 10 mg by mouth from day 5 to day 24 of the menstrual cycle
Trial: 8071049
Drug: Iopromide (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iopromide (300 mg I/kg)
Trial: 8071049
Drug: Ioversol (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ioversol (300 mg I/kg)
Trial: 8071049
Drug: Iopamidol (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iopamidol (300 mg I/kg)
Trial: 2895662
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (bendrofluazide or propranolol)
Trial: 24392599
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily insulin glargine (GL)
Trial: 9175175
Drug: Powdered ginger
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Powdered ginger 4 g daily for 3 months
Trial: 9175175
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of powdered ginger 10 g
Trial: 9175175
Drug: Fenugreek 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenugreek 2.5 g twice daily for 3 months to healthy individuals
Trial: 9175175
Drug: Fenugreek 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenugreek 2.5 g twice daily for 3 months to CAD patients with NIDDM
Trial: 9175175
Drug: Fenugreek 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenugreek 2.5 g twice daily for 3 months to NIDDM (non-CAD) patients
Trial: 9175175
Drug: Fenugreek 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenugreek 2.5 g twice daily for 3 months to severe NIDDM cases
Trial: 9175175
Drug: Fenugreek administration
RxNorm normalized name: FENUGREEK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenugreek administration
Trial: 8439216
Drug: Prolonged glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged glucose administration (250-300 g/day)
Trial: 22481647
Drug: Nail lacquer
RxNorm normalized name: Penlac Nail Lacquer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nail lacquer containing ciclopirox 8% applied once weekly
Trial: 20154483
Drug: Oral beclomethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral beclomethasone dipropionate (BDP) administration
Trial: 18584525
Drug: Triple antiviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple antiviral induction therapy: amantadine hydrochloride and ribavirin, combined with 6 weeks interferon alfa‐2b (weeks 1‐2: 18 MU/day, weeks 3‐4: 9 MU/day, weeks 5‐6: 6 MU/day), thereafter combined with weekly peginterferon alfa‐2b
Trial: 18584525
Drug: Treatment-naive patients
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-naive patients with HCV RNA <5 IU/mL at week 1 or 2
Trial: 18584525
Drug: Treatment-naive patients
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-naive patients with HCV RNA >or=5 IU/mL at week 16
Trial: 18584525
Drug: Previous non‐responders/relapsers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Previous non‐responders/relapsers with HCV RNA <5 IU/mL at week 2
Trial: 18584525
Drug: Previous non‐responders/relapsers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Previous non‐responders/relapsers with HCV RNA >or=5 IU/mL at week 8
Trial: 11059861
Drug: Intravenous ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ciprofloxacin 200 mg/12 h for 7 days (group A)
Trial: 11059861
Drug: Intravenous ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ciprofloxacin 200 mg/12 h for 2 days followed by oral ciprofloxacin 500 mg/12 h for 5 days (group B)
Trial: 9082266
Drug: Intravenous fentanyl-droperidol
RxNorm normalized name: droperidol / fentanyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous fentanyl-droperidol
Trial: 8375123
Drug: Rectal morphine
RxNorm normalized name: morphine Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal morphine administration
Trial: 31277165
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (3 cycles of combination therapy with carboplatin and nab‐paclitaxel)
Trial: 27890714
Drug: Amikacin Fosfomycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amikacin Fosfomycin Inhalation System (AFIS) - 300 mg amikacin/120 mg fosfomycin, delivered by aerosol twice daily for 10 days (or to extubation if < 10 days) via the investigational eFlow Inline System.
Trial: 27890714
Drug: Placebo (saline),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline), delivered by aerosol twice daily for 10 days (or to extubation if < 10 days) via the investigational eFlow Inline System.
Trial: 27890714
Drug: Amikacin Fosfomycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amikacin Fosfomycin Inhalation System (AFIS)
Trial: 15064259
Drug: 5-HT3 receptor
RxNorm normalized name: 5-HT3 receptor antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-HT3 receptor antagonists combined with droperidol
Trial: 15064259
Drug: 5-HT3 receptor
RxNorm normalized name: 5-HT3 receptor antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-HT3 receptor antagonists combined with dexamethasone
Trial: 15064259
Drug: 5-HT3 receptor
RxNorm normalized name: 5-HT3 receptor antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-HT3 receptor antagonists alone
Trial: 11192362
Drug: Metoprolol CR/XL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol CR/XL (200 mg once daily)
Trial: 8478543
Drug: Traditional surveillance
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional surveillance system and monthly physician questionnaires
Trial: 3823636
Drug: Caffeine (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (6 mg/kg body weight; equivalent to approximately 4 cups of coffee)
Trial: 17020971
Drug: ZAP-70 positive
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ZAP-70 positive CC genotypes
Trial: 14617471
Drug: Ketamine general
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine general anaesthesia with 0.6 mg atropine and 10 mg diazepam premedication
Trial: 14617471
Drug: Ketamine general
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine general anaesthesia with 0.6 mg atropine and 50 mg promethazine premedication
Trial: 14617471
Drug: Ketamine general
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine general anaesthesia with only 0.6 mg atropine
Trial: 10081520
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid 5 mg daily
Trial: 9173652
Drug: Normovolemic haemodilution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normovolemic haemodilution with Ringer solution
Trial: 28044450
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg theanine
Trial: 28044450
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg caffeine + 200 mg theanine
Trial: 28044450
Drug: 0 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg caffeine + 0 mg theanine (placebo)
Trial: 24912486
Drug: Conventional oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional oxygen therapy (OT)
Trial: 19687032
Drug: Remifentanil (Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil (Group R) - continuous infusion titrated between 3 and 4 ng ml‐1